FDA approved Dawnzera in US as first and only RNA-targeted prophylactic treatment for hereditary angioedema
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
The accelerated approval is supported by results from part 1 of the ESSENCE trial
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
Inclacumab was generally well tolerated in THRIVE-131
The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
Attorney General Ken Paxton sued pharmaceutical giant Eli Lilly for bribing and illegally inducing medical providers to prescribe its most profitable drugs
Subscribe To Our Newsletter & Stay Updated